Trial · NCT06040320
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
NCT06040320, Phase 1, Phase 2, Active not recruiting, Washington University School of Medicine
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD). Trials, record NCT06040320. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06040320
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
- NCT number
- NCT06040320
- Status
- Active not recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Post-transplant Lymphoproliferative Disorder
- Interventions
- Polatuzumab vedotin, Rituximab, CHP
- First posted
- 2023-09-15
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frequency and severity of treatment-related adverse events (AEs) | From start of treatment through 30 days after completion of treatment or initiation of alternative therapy (estimated to be 5-7 months) | |
| Primary | Number of dose-limiting toxicities (DLTs) (Safety Lead-In Cohort only) | From start of treatment through cycle 2 (estimated to be 42 days, each cycle is 21 days) | A dose-limiting toxicity (DLT) is defined as an occurrence of an adverse event delineated by the protocol that is at least possibly related to polatuzumab vedotin, rituximab, or the combination within Cycle 1 or Cycle 2. |
| Primary | Rate of completion of the regimen | Through completion of treatment (estimated to be 4-6 months) | |
| Secondary | Complete metabolic response (CR) rate by PET/CT | After cycle 2 (estimated to be day 42, each cycle is 21 days) | -Per Lugano Response Criteria |
| Secondary | Complete metabolic response (CR) rate by PET/CT | End of treatment (estimated to be between 4-6 months) | -Per Lugano Response Criteria |
| Secondary | Overall response rate (ORR) | End of treatment (estimated to be between 4-6 months) | * Per Lugano Response Criteria * Overall Response Rate: The proportion of patients who have a complete or partial response to therapy. |
| Secondary | Best overall response | Through completion of treatment (estimated to be between 4-6 months) | * Per Lugano Response Criteria * Best Overall Response: Best response recorded from start of treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). |
| Secondary | Duration of response | Through 5 years from completion of treatment (estimated to be between 64 and 66 months) | * Per Lugano Response Criteria * Duration of Response: The time from onset of response to disease progression or death in patients who achieve complete or partial response. |
| Secondary | Progression-free survival (PFS) | Through 5 years from completion of treatment (estimated to be between 64 and 66 months) | * Per Lugano Response Criteria * Progression-Free Survival: The time from initiation of treatment to the occurrence of disease progression or death. |
| Secondary | Overall survival (OS) | Through 5 years from completion of treatment (estimated to be between 64 and 66 months) | -Overall Survival: The time from initiation of treatment to death. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06040320
GET https://conductscience.org/api/trials/v1/NCT06040320/registered